Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Impresses on Earnings

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) beat their Q4 2016 analyst forecast both on an EPS and revenue basis. Q4 EPS was a loss of $0.35 – beating estimates by $0.05. Q4 revenues were $2.6 million – beating estimates by $0.86 million. For 2016, device and related revenue was $13.3 million. Gross profit for the year ended December 31, 2016 was $2.9 million, of which $2.6 million was attributable to device and related revenue.

Thomas Looby, president and chief executive officer at Ekso Bionics Holdings, Inc. (NASDAQ:EKSO). “With the broadest label in the US for exoskeletons, a sales and marketing team that is highly motivated and already making major inroads, a clinical study to provide evidence, and a technology that is changing lives, we have certainly had a productive 2016 and I am energized to lead this company into 2017 and beyond.”

Ekso Bionics, Inc. (NASDAQ:EKSO) designs, engineers, and develops robotic exoskeletons. In 2016, Ekso Bionics received the first FDA clearance exoskeleton for use with stroke and spinal cord injury levels to C7. Ekso Bionics is headquartered in Northern California.

Ekso Bionics went public in 2016. Their EPS history is a loss in 2014 of $30.2 which they narrowed in 2015 to an EPS loss of $1.66. Sales have an upward trend. In 2014 sales came in at $5.3 million but were $8.7 million in 2015. All four firms that follow Ekso Bionics, Inc. (NASDAQ:EKSO) rate EKSO shares as a “Strong Buy” with a consensus price target of $12.50 – about four times current trading levels.

Ticker Symbol EKSO
Last Price a/o 5:40 PM EST  $                      3.40
Average Volume                    110,000
Market Cap (mlns)  $                    70.45
Sales (mlns) $13.60
Shares Outstanding (mlns) 21.81
Share Float (mlns) 18.73
Shortable Yes
Optionable Yes
Inside Ownership 0.10%
Short Float 3.21%
Short Interest Ratio 5.51
Quarterly Return -24.36%
YTD Return -18.84%
Year Return 0.00%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy. 

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading.

Previous ArticleNext Article
Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Leave a Reply

Your email address will not be published. Required fields are marked *